Our free daily oncology focused e-news service.

Featured Oncology News

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

(Lilly) Mar 5, 2021 - Loxo Oncology at Lilly today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial in relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other non-Hodgkin's lymphomas. Pirtobrutinib is an investigational, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor.

read corporate press release

Association of Community Cancer Centers Names New President: Krista Nelson, MSW, LCSW, OSW-C, FAOSW

(ACCC) Mar 5, 2021 - Krista Nelson, MSW, LCSW, OSW-C, FAOSW was named president of the Association of Community Cancer Centers (ACCC) today at the association’s virtual 47th Annual Meeting and Cancer Center Business Summit. Nelson will lead the organization for the next year, as oncology professionals work to tackle critical issues in cancer care post-pandemic. Nelson is Program Manager of Compassion and Senior Social Worker at Providence Cancer Institute at Providence Health and Services in Portland, Oregon. Krista serves in clinical, research, and program management roles. As a volunteer, she provides psychosocial care to the houseless community in Portland with Portland Street Medicine. She has served on numerous ACCC committees, and on the Executive Committee and Board of Trustees for 5 years.

read press release

Oncology Clinical News

Childhood Cancer Survivors, Providers Satisfied with Video Visits for Long-term Follow-up

(Dana-Farber) Mar 4, 2021 - When the COVID-19 pandemic limited in-person medical checkups last year, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, for the first time, offered video visits for long-term follow-up appointments for childhood cancer survivors.

read press release

Earlier Colonoscopies Halve Subsequent Cancer Risk

(Scope Blog/Stanford Medicine) Mar 4, 2021 - Researchers have the real-world data from nearly 3 million people to show that initiating colonoscopy screening between the ages of 45 and 49 halves the risk of subsequent development of colorectal cancers. They published their findings recently in Gastroenterology.

read article

Collagen Plays Protective Role During Pancreatic Cancer Development

(MD Anderson) Mar 4, 2021 - Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts may not promote cancer development but instead plays a protective role in controlling pancreatic cancer progression, reports a new study from researchers at The University of Texas MD Anderson Cancer Center.

read press release

Engineered 'Off the Shelf' Stem Cells Target Breast Cancer that Metastasizes to the Brain

(BWH) Mar 3, 2021 - Approximately 15-to-30 percent of patients with metastatic breast cancer have brain metastasis (BM), with basal-like breast cancer (BLBC) metastasizing to the brain most frequently.

read article

Original Error

(Harvard Medical School) Mar 4, 2021 - There is no stronger risk factor for cancer than age. At the time of diagnosis, the median age of patients across all cancers is 66.

read article

Immutep Expands Part B of TACTI-002 Study

(Yahoo! Finance) Mar 5, 2021 - Immutep Limited a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design.

read article

Oncology Business and Policy News

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics

(Markets Insider) Mar 4, 2021 - ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced a collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Under the terms of the agreement, ALX Oncology and Tallac will share equally in the cost of research and development and any profits or losses incurred.

read article